Bryan Wahl Sells 4,084 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 4,084 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $283,511.28. Following the transaction, the general counsel owned 72,315 shares in the company, valued at approximately $5,020,107.30. This represents a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 19th, Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00.
• On Wednesday, March 18th, Bryan Wahl sold 4,125 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total value of $283,428.75.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $64.51 on Friday. The company’s fifty day simple moving average is $69.12 and its 200-day simple moving average is $70.22. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The firm has a market cap of $2.75 billion, a PE ratio of -39.82 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. lifted its position in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares in the last quarter. State of Wisconsin Investment Board grew its position in Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after purchasing an additional 332 shares in the last quarter. Federated Hermes Inc. grew its position in Tarsus Pharmaceuticals by 0.6% in the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after purchasing an additional 339 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after buying an additional 392 shares during the last quarter. Finally, Creative Planning increased its stake in Tarsus Pharmaceuticals by 3.3% in the 3rd quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after buying an additional 393 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TARS shares. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Finally, Guggenheim boosted their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.